Teclison

Teclison is a biotechnology company founded in 2014 with a mission to develop groundbreaking therapies for cancer. Specializing in the development of innovative cancer medicines, Teclison's approach focuses on inducing tumor necrosis and enhancing anti-tumor immunity for long-term cancer remission. The company's drug is designed to target any solid tumor with a predilection for liver metastasis, prioritizing hepatocellular carcinoma and metastatic colorectal cancer initially, with plans to expand to other solid tumors with liver metastasis. A first-in-class hypoxia-activating agent forms the basis of Teclison's novel approach, creating high local concentrations within tumors and producing profound hypoxia exclusively within the tumor. The company's latest milestone involves securing a $5.90M venture round investment on 14th February 2022, with participation from Nestor Capital and WTT Investment.